Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

NCT02416232 ·Status: NO_LONGER_AVAILABLE

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

NCT01271803 ·Status: COMPLETED ·Phase: PHASE1

Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma

NCT03416933 ·Status: COMPLETED ·Phase: NA

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

NCT03514901 ·Status: UNKNOWN ·Phase: PHASE2

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

NCT02583516 ·Status: COMPLETED ·Phase: PHASE2

Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma

NCT06557291 ·Status: COMPLETED

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

NCT01436656 ·Status: COMPLETED ·Phase: PHASE1

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

NCT01990248 ·Status: COMPLETED

Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors

NCT01878396 ·Status: UNKNOWN

Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain

NCT03605771 ·Status: RECRUITING

Utility of Novel BRAF Test for Melanoma

NCT01840527 ·Status: COMPLETED

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

NCT07092410 ·Status: WITHDRAWN ·Phase: PHASE4

Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis

NCT02537600 ·Status: COMPLETED ·Phase: PHASE2

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

NCT03391050 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis

NCT05510466 ·Status: UNKNOWN

Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes

NCT02310451 ·Status: COMPLETED ·Phase: NA

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma

NCT02410863 ·Status: TERMINATED ·Phase: PHASE2

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain

NCT01266967 ·Status: COMPLETED ·Phase: PHASE2

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma

NCT05304546 ·Status: COMPLETED ·Phase: PHASE2

Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

NCT02902029 ·Status: COMPLETED ·Phase: PHASE2

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

NCT04759846 ·Status: WITHDRAWN ·Phase: PHASE1

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

NCT04417621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK

NCT03553329 ·Status: COMPLETED

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

NCT02828202 ·Status: RECRUITING

Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma

NCT06251934 ·Status: COMPLETED